LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor.
Industry veteran brings more than 20 years of broad operational experience in emerging-stage, private and publicly traded biotechnology companies with an ...